News FDA Clears Ranibizumab for Myopic Choroidal Neovascularization by Medscape • 2017/01/06 • 0 Comments Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV. FDA Approvals Full Story →